Blood · 1995 · 55 citations · 28 references
MedicineCell BiologyHematologyHematologic OncologyHematopathologyTransfusion MedicineAnemiaBone Marrow EvaluationBone Marrow PathologyClinical HematologyHematologic DisordersHematologic PathologyBone Marrow AssessmentParoxysmal Nocturnal Hemoglobinuria Therapy
The lack of glycosylphosphatidylinositol (GPI)-anchored membrane proteins such as decay-accelerating factor (DAF) and CD59 on blood cells has a diagnostic value in paroxysmal nocturnal hemoglobinuria (PNH). Because PNH often develops in patients with aplastic anemia (AA), we attempted to detect a PNH clone in the bone marrow (BM) of patients with AA and pancytopenia before affected cells were evident in the peripheral blood (PB). We used flow cytometry with monoclonal antibodies against DAF and CD59 for the detection of the clone. Affected cells were observed in the BM of 3 of 7 patients with AA and 1 of 3 patients with pancytopenia of unknown origin, but not in their PB. All 8 patients with apparent PNH had affected cells in their BM and PB. On the basis of the early appearance of the PNH clone in the BM, a prospective 4-month follow-up study of the PB cells was performed. The study showed the release of affected mature cells first in granulocytes, then in monocytes, and finally in lymphocytes. Ham's test was positive before affected erythrocytes were detected by flow cytometry. Our findings indicate that detection of the PNH clone in BM could be predictive of the development of PNH in patients with AA and pancytopenia.
28
A Nicholson-Weller, JP March, S I Rosenfeld et al. · Proceedings of the National Academy of Sciences · 1983 · 434 citations · Full text
Medicine, Hematology, Immunology +17
Late haematological complications in severe aplastic anaemia
André Tichelli, Aloïs Gratwohl, A. Würsch et al. · British Journal of Haematology · 1988 · 284 citations